| [1] |
Ji Zhu,Ye Xu,Zhen Z, et al.Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era－ identification of the high risk patients.Radiation Oncology, 2010, 5: 118.
|
| [2] |
Sauer R,Becker H,Hohenberger W, et al.Preoperative versus postoperative chemoradiotherapy for rectal cancer.N Engl J Med, 2004, 351(17): 1731-1740.
|
| [3] |
Sebag－Montefi,Stephens RJ,Steele R, et al.Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer(MRC CR07 and NCIC－CTG C016)：a multicentre, randomised trial.Lancet, 2009, 373: 811-820.
|
| [4] |
Peng J,Sheng W,Huang D, et al.Perineural invasion in pT3N0 rectal cancer：the incidence and its prognostic effect.Cancer, 2011, 117(7): 1415-1421.
|
| [5] |
Merkel S,Mansmann U,Siassi M, et al.The prognostic inhomogeneity in pT3 rectal carcinomas.International Journal of Colorectal Disease, 2001, 16(5): 298-304.
|
| [6] |
Shin R,Jeong SY,Yoo HY, et al.Depth of mesorectal extension has prognostic significance in patients with T3 rectal cancer.Dis Colon Rectum, 2012, 55(12): 1220-1228.
|
| [7] |
RSNA.Radiology reporting templates.2014－05－27.
URL
|
| [8] |
Kaur H,Choi H,You YN, et al.MR imaging for preoperative evaluation of primary rectal cancer：practical considerations.Radiographics, 2012, 32(2): 389-409.
|
| [9] |
MERCURY.Extramural depth of tumor invasion at thin－section MR in patients with rectal cancer：results of the MERCURY study.Radiology, 2007, 243(1): 132-139.
|
| [10] |
Glimelius B,Tiret E,Cervantes A, et al.Rectal cancer：ESMO clinical practice guidelines for diagnosis, treatment and follow－up.Ann Oncol, 2013, 24(6): 81-88.
|
| [11] |
Hanly AM1,Ryan EM,Rogers AC, et al.Multicenter evaluation of rectal cancer reImaging post neoadjuvant(MERRION)therapy.Ann Surg, 2014, 259(4): 723-727.
|
| [12] |
Hein PA,Kremser C,Judmaier W, et al.Diffusion－weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation：preliminary results of a prospective study.Eur J Radiol, 2003, 45(3): 214-222.
|
| [13] |
Shihab OC,Taylor F,Salerno G, et al.MRI predictive factors for long－term outcomes of low rectal tumours.Ann SurgOncol, 2011, 18(12): 3278-384.
|
| [14] |
van Stiphout RG,Lammering G,Buijsen J, et al.Development and external validation of a predictive model for pathological complete response of rectal cancer patients including sequential PET－CT imaging.RadiotherOncol, 2011, 98(1): 126-133.
|
| [15] |
Sun W,Xu J,Hu W, et al.The role of sequential 18(F)－FDG PET/CT in predicting tumour response after preoperative chemoradiation for rectal cancer.Colorectal Dis, 2013, 15(5): 231-238.
|
| [16] |
Capirci C,Rubello D,Chierichetti F, et al.Long－term prognostic value of18F－FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvantradiochemotherapy.AJR Am J Roentgenol, 2006, 187(2): 202-208.
|
| [17] |
Maas M,Nelemans PJ,Valentini V, et al.Long－term outcome in patients with a pathological complete response after chemoradiation for rectal cancer：a pooled analysis of individual patient data.Lancet Oncol, 2010, 11(9): 835-844.
|
| [18] |
Habr－Gama A,Perez RO,Nadalin W, et al.Operative versus nonoperativetreatment for stage 0 distal rectal cancer following chemoradiationtherapy：long－term results.Ann Surg, 2004, 240(4): 711-718.
|
| [19] |
Habr－Gama A,Gama－Rodrigues J,São Julião GP, et al.Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvantchemoradiation：impact of salvage therapy on local disease control.Int J RadiatOncolBiolPhys, 2014, 88(4): 822-828.
|
| [20] |
Belluco C,De Paoli A,Canzonieri V, et al.Long－term outcome of patients with complete pathologic response after neoadjuvantchemoradiation for cT3 rectal cancer：implications for local excision surgical strategies.Ann SurgOncol, 2011, 18(13): 3686-3693.
|
| [21] |
Hong YS,Nam BH,Kim KP, et al.Adjuvant chemotherapy with oxaliplatin/5－fluorouracil/leucovorin(FOLFOX)versus 5－fluorouracil/leucovorin(FL)for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy：Updated results of 3－year disease－free survival from a randomizedphase II study(The ADORE). ASCO Proceeding, 2014: 3502.
|
| [22] |
Schrag D,Weiser MR,Goodman KA, et al.Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locallyadvanced rectal cancer：a pilot trial.J ClinOncol, 2014, 32(6): 513-518.
|
| [23] |
Tan BR,Thomas F,Myerson RJ, et al.Thymidylatesynthase genotype－directed neoadjuvantghemoradiationfor patients with rectal adenocarcinoma JClinOncol, 2011, 29(7): 875-883.
|